Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48 + Toripalimab in Cisplatin-Ineligible MIBC
NCT06341400Phase 2Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jun 2024
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, toripalimab in bladder carcinoma, sponsored by Southern Medical University Zhujiang Hospital. Started Jun 2024; status: recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
bladder carcinoma
Beyond the preview
Go deeper on NCT06341400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341400.